Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-08 07:30 |
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response …
|
English | 74.4 KB | ||
| 2025-12-08 07:30 |
ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux…
|
French | 94.8 KB | ||
| 2025-12-03 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 83.4 KB | ||
| 2025-12-03 22:30 |
Monthly information on share capital and company voting rights
|
English | 85.2 KB | ||
| 2025-11-27 13:40 |
Cellectis organise un webinaire dédié aux actionnaires français le jeudi 4 déce…
|
French | 70.4 KB | ||
| 2025-11-19 12:18 |
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing P…
|
English | 188.0 KB | ||
| 2025-11-19 12:18 |
Cellectis publie un article dans Nature Communications sur un procédé d’édition…
|
French | 165.9 KB | ||
| 2025-11-07 22:30 |
Cellectis publie ses résultats financiers du troisième trimestre 2025 et une mi…
|
French | 265.6 KB | ||
| 2025-11-07 22:30 |
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Up…
|
English | 270.7 KB | ||
| 2025-11-07 17:30 |
Monthly information on share capital and company voting rights
|
English | 84.9 KB | ||
| 2025-11-07 17:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 157.8 KB | ||
| 2025-11-03 15:15 |
Cellectis to Present a Development Update for eti-cel at ASH 2025
|
English | 210.1 KB | ||
| 2025-11-03 15:15 |
Cellectis présentera de nouvelles avancées sur éti-cel lors du congrès annuel d…
|
French | 240.4 KB | ||
| 2025-10-31 21:30 |
Cellectis publiera ses résultats financiers du troisième trimestre le 7 novembr…
|
French | 142.9 KB | ||
| 2025-10-31 21:30 |
Cellectis to Report Third Quarter Financial Results on November 7, 2025
|
English | 127.9 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
